期刊
ALZHEIMERS & DEMENTIA
卷 18, 期 11, 页码 2199-2208出版社
WILEY
DOI: 10.1002/alz.12519
关键词
Alzheimer's disease; mild behavioral impairment; neuropathology; neuropsychiatric symptoms
资金
- NIA/NIH [U01 AG016976]
- NIA [P30AG019610, P30 AG013846, P50 AG008702, P50 AG025688, P50 AG047266, P30 AG010133, P50 AG005146, P50 AG005134, P50 AG016574, P50 AG005138, P30 AG008051, P30 AG013854, P30 AG008017, P30 AG010161]
- National Institute of Aging [P50 AG047366, P30 AG010129, P50 AG016573, P50 AG005131, P50 AG023501, P30 AG035982, P30 AG028383, P30 AG053760, P30 AG010124, P50AG005133, P50AG005142, P30 AG012300, P30 AG049638, P50 AG005136, P50 AG033514, P50 AG005681, P50 AG047270]
- Alzheimer's Drug Discovery Foundation [2016354]
- Alzheimer's Association [PTCG-20-700751]
- Canadian Institutes of Health Research
- Neuropsychiatric Symptoms team (Team 11) of the Canadian Consortium on Neurodegeneration in Aging [CAN 163902]
- Weston Brain Institute [CT190002]
- National Institute on Aging [R01AG046543]
- Canadian Institutes of Health Research Post-doctoral Fellowship Research Award
- Brain Canada
- Lundbeck
- Otsuka
- Alzheimer Society of Canada
- Axovant Sciences Ltd.
- Roche
- Brain & Behavior Research Foundation
This study found that mild behavioral impairment (MBI) is a predictor of progression to Alzheimer's disease (AD). MBI and its domains, particularly psychosis, were associated with clinically-diagnosed AD and neuropathology-confirmed AD.
Introduction Mild behavioral impairment (MBI) is characterized by later-life emergence of neuropsychiatric symptoms. Investigating its relationship with progression to Alzheimer's disease (AD) would provide insight on its importance as a predictor of AD. Methods Cognitively normal participants (N = 11,372) from the National Alzheimer's Coordinating Center were stratified by MBI status, using the Neuropsychiatric Inventory-Questionnaire. We investigated whether MBI and its domains were predictors of progression to clinically-diagnosed AD. MBI as a predictor of progression to neuropathology-confirmed AD was also investigated in those with neuropathological data. Results Six percent (N = 671) of participants progressed to AD. MBI (N = 2765) was a significant predictor of progression to clinically-diagnosed (hazard ratio [HR] = 1.75) and neuropathology-confirmed AD (HR = 1.59). MBI domains were also associated with clinically-diagnosed AD, with psychosis having the greatest effect (HR = 6.49). Discussion These findings support the biological underpinnings of MBI, emphasizing the importance of later life behavioral changes in dementia detection and prognostication.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据